-
Study aim
-
The aim of this study was to find a way to reduce vaginal delivery pain in Nullipar and Full-term women.
-
Design
-
Non-randomized clinical trial with control group
-
Settings and conduct
-
It will be explained to patients about how pain is assessed. Then, in the intervention group, after the onset of the active phase of labor, Dexmedetomidine will be given according to the protocol and will continue until episiotomy is performed. There is no intervention in the control group to reduce pain. Patients in both groups will be evaluated for pain intensity and sedation every 5 minutes. 15 minutes after placenta delivery, the patient and midwife of both groups will be evaluated in terms of satisfaction.
-
Participants/Inclusion and exclusion criteria
-
All pregnant women, full term, nullipara, ASA CLASS 1 & 2, who will be candidate for pain relief through intravenous medications, will be included in the study.
Patients with liver failure, kidney failure, grade 2 or 3 heart block,the use of psychiatric drugs, addicts to narcotic drugs will not be included in the study.
-
Intervention groups
-
In the intervention group, after the onset of the active phase of labor, the initial dose (1 μg / kg ) of intravenous Dexmedetomidine (Manufacturing of Exir Pharmaceutical Company) will be infused over a 10 minute period, and then a continuous dose of 0.2 μg / kg / hour starts and with increased pain, visual analog scale score > 3, the infusion dose will gradually increase to a maximum of 1 μg / kg . And will continue until episiotomy. There is no intervention in the control group to reduce pain.
-
Main outcome variables
-
Change in severity of labor pain